Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses

被引:54
作者
Gadducci, A
Baicchi, U
Marrai, R
Ferdeghini, M
Bianchi, R
Facchini, V
机构
[1] UNIV PISA,INST NUCL MED,PISA,ITALY
[2] SANTA CHIARA HOSP,BLOOD BANK,PISA,ITALY
关键词
D O I
10.1006/gyno.1996.0025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plasma levels of D-dimer (DD) and CA 125 were measured preoperatively in 121 patients with ovarian masses submitted to laparotomy. DD and CA 125 levels were higher in the 56 patients with epithelial ovarian cancer than in the 65 patients with benign ovarian disease (P < 0.0001). The logistic regression procedure showed that both DD assay (cutoff 416 ng/ml) and CA 125 assay (cutoff 65 U/ml) were significant predictive variables for malignancy (P = 0.0001). The concordance between predicted probabilities and observed responses was 75.7% for DD, 72.1% for CA 125, and 90.8% for DD and CA 125. It is worth noting that DD was increased (>416 ng/ml) in 73% of FIGO stage I patients, whereas CA 125 was above 65 U/ml in only 33.3%. Sensitivity, specificity, positive predictive value, and negative predictive value of the tests in differentiating benign from malignant ovarian masses were as follows: 76.8, 93.8, 91.5, and 82.4%, respectively, for CA 125; 94.6, 76.9, 77.9, and 94.3%, respectively, for the combination CA 125 or DD; and 73.2, 100.0, 100.0, and 81.3%, respectively, for the combination CA 125 and DD. The combination CA 125 and DD seems to be a useful diagnostic tool to differentiate benign from malignant ovarian masses. Elevated preoperative levels of both antigens are invariably associated with a postsurgical diagnosis of epithelial ovarian cancer. (C) 1996 Academic Press, Inc.
引用
收藏
页码:197 / 202
页数:6
相关论文
共 30 条
  • [1] COAGULATION ABNORMALITIES IN MALIGNANCY - A REVIEW
    BICK, RL
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1992, 18 (04) : 353 - 372
  • [2] TRANS-ABDOMINAL ULTRASOUND SCREENING FOR EARLY OVARIAN-CANCER
    CAMPBELL, S
    BHAN, V
    ROYSTON, P
    WHITEHEAD, MI
    COLLINS, WP
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1989, 299 (6712): : 1363 - 1367
  • [3] EINHORN N, 1986, OBSTET GYNECOL, V67, P414
  • [4] FINKLER NJ, 1988, OBSTET GYNECOL, V72, P659
  • [5] THE CONCOMITANT DETERMINATION OF DIFFERENT TUMOR-MARKERS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER AND BENIGN OVARIAN MASSES - RELEVANCE FOR DIFFERENTIAL-DIAGNOSIS
    GADDUCCI, A
    FERDEGHINI, M
    PRONTERA, C
    MORETTI, L
    MARIANI, G
    BIANCHI, R
    FIORETTI, P
    [J]. GYNECOLOGIC ONCOLOGY, 1992, 44 (02) : 147 - 154
  • [6] PRETREATMENT PLASMA-LEVELS OF FIBRINOPEPTIDE-A (FPA), D-DIMER (DD), AND VON-WILLEBRAND-FACTOR (VWF) IN PATIENTS WITH OVARIAN-CARCINOMA
    GADDUCCI, A
    BAICCHI, U
    MARRAI, R
    DELBRAVO, B
    FOSELLA, PV
    FACCHINI, V
    [J]. GYNECOLOGIC ONCOLOGY, 1994, 53 (03) : 352 - 356
  • [7] GADDUCCI A, 1991, CANCER J - FRANCE, V4, P249
  • [8] MACROSCOPIC CHARACTERIZATION OF OVARIAN-TUMORS AND THE RELATION TO THE HISTOLOGICAL DIAGNOSIS - CRITERIA TO BE USED FOR ULTRASOUND EVALUATION
    GRANBERG, S
    WIKLAND, M
    JANSSON, I
    [J]. GYNECOLOGIC ONCOLOGY, 1989, 35 (02) : 139 - 144
  • [9] HAFTER R, 1985, SCAND J CLIN LAB INV, V45, P137
  • [10] HERRMANN UJ, 1987, OBSTET GYNECOL, V69, P777